Pitfalls associated with commonly used methods for pharmacoeconomic analyses

Research output: Contribution to journalReview article

9 Citations (Scopus)

Abstract

Demonstrating the economic value of treatment has become an important objective of many clinical trials. Awareness of the limitations of the methods used in pharmacoeconomic studies of infectious diseases will help in understanding why improved methods are needed to adequately describe the costs associated with infectious episodes. Current analyses generally consider three levels of cost and use three methods to determine costs associated with an infectious episode. However, these costs and the methods for obtaining them may not be appropriate in all studies. Future pharmacoeconomic research needs to adhere to established principles but embrace new methodologies to improve the validity and usefulness of these studies.

Original languageEnglish (US)
JournalPharmacotherapy
Volume22
Issue number2 II
StatePublished - Feb 11 2002
Externally publishedYes

Fingerprint

Pharmaceutical Economics
Costs and Cost Analysis
Communicable Diseases
Economics
Clinical Trials
Research

ASJC Scopus subject areas

  • Pharmacology (medical)
  • Pharmacology, Toxicology and Pharmaceutics(all)

Cite this

Pitfalls associated with commonly used methods for pharmacoeconomic analyses. / Klepser, Donald G.

In: Pharmacotherapy, Vol. 22, No. 2 II, 11.02.2002.

Research output: Contribution to journalReview article

@article{a52af4a31d70452688de6eafdf900d4a,
title = "Pitfalls associated with commonly used methods for pharmacoeconomic analyses",
abstract = "Demonstrating the economic value of treatment has become an important objective of many clinical trials. Awareness of the limitations of the methods used in pharmacoeconomic studies of infectious diseases will help in understanding why improved methods are needed to adequately describe the costs associated with infectious episodes. Current analyses generally consider three levels of cost and use three methods to determine costs associated with an infectious episode. However, these costs and the methods for obtaining them may not be appropriate in all studies. Future pharmacoeconomic research needs to adhere to established principles but embrace new methodologies to improve the validity and usefulness of these studies.",
author = "Klepser, {Donald G}",
year = "2002",
month = "2",
day = "11",
language = "English (US)",
volume = "22",
journal = "Pharmacotherapy",
issn = "0277-0008",
publisher = "Pharmacotherapy Publications Inc.",
number = "2 II",

}

TY - JOUR

T1 - Pitfalls associated with commonly used methods for pharmacoeconomic analyses

AU - Klepser, Donald G

PY - 2002/2/11

Y1 - 2002/2/11

N2 - Demonstrating the economic value of treatment has become an important objective of many clinical trials. Awareness of the limitations of the methods used in pharmacoeconomic studies of infectious diseases will help in understanding why improved methods are needed to adequately describe the costs associated with infectious episodes. Current analyses generally consider three levels of cost and use three methods to determine costs associated with an infectious episode. However, these costs and the methods for obtaining them may not be appropriate in all studies. Future pharmacoeconomic research needs to adhere to established principles but embrace new methodologies to improve the validity and usefulness of these studies.

AB - Demonstrating the economic value of treatment has become an important objective of many clinical trials. Awareness of the limitations of the methods used in pharmacoeconomic studies of infectious diseases will help in understanding why improved methods are needed to adequately describe the costs associated with infectious episodes. Current analyses generally consider three levels of cost and use three methods to determine costs associated with an infectious episode. However, these costs and the methods for obtaining them may not be appropriate in all studies. Future pharmacoeconomic research needs to adhere to established principles but embrace new methodologies to improve the validity and usefulness of these studies.

UR - http://www.scopus.com/inward/record.url?scp=0036153857&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036153857&partnerID=8YFLogxK

M3 - Review article

VL - 22

JO - Pharmacotherapy

JF - Pharmacotherapy

SN - 0277-0008

IS - 2 II

ER -